Curis Inc (CRIS, Financial), a biotechnology company, experienced a significant stock price increase of 5.46%. The stock is currently trading at $4.25 per share with a trading volume of 21,545 shares, a turnover rate of 0.25%, and a price fluctuation of 4.71%.
Recent financial reports indicate that Curis Inc achieved a revenue of $2.93 million, but reported a net loss of $10.09 million, translating to an earnings per share (EPS) of -$1.70. The company's gross profit stands at $2.85 million, with a price-to-earnings (P/E) ratio of -0.54.
In terms of analyst ratings, out of five participating institutions, 80% have recommended buying the stock, while 20% suggest holding it. No institutions have recommended selling.
Within the biotechnology sector, where Curis Inc operates, the overall growth was 0.53%. Notable gainers in the sector include Neurosense Therapeutics Ltd, Protagenic Therapeutics Inc, and Rocket Pharmaceuticals Inc. Active stocks with high turnover rates include Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc. Stocks with significant price fluctuations include Neurosense Therapeutics Ltd, Silexion Therapeutics Corp, and Protagenic Therapeutics Inc.
Curis Inc specializes in developing and commercializing innovative drugs and therapies in immuno-oncology and precision oncology. Their product pipeline targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, and hematological cancers, including products like CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.
